Navigation Links
Article Published in Expert Opinion on Biological Therapy Evaluates StemEx(R) (carlecortemcel-l) for Leukemia and Lymphoma
Date:9/30/2009

JERUSALEM, Israel, September 30 /PRNewswire/ -- Gamida Cell announced today the publication of an article evaluating carlecortemcel-l, the generic name of what is widely known as "StemEx", as a therapy for blood cancers such as leukemia and lymphoma. The article, carlecortemcel-l, an ex vivo expanded umbilical cord blood cell graft for allogeneic transplantation, written by Dr. Ka Wah Chan and Dr. Demetrios Petropoulos, will be published in the November 2009 issue of Expert Opinion on Biological Therapy. It is now available for online review at (http://informahealthcare.com/doi/abs/10.1517/14712590903321447).

Dr. Chan is the director of the Hematology/Oncology and Blood and Marrow Stem Cell Transplant Programs at the Texas Transplant Institute on the campus of Methodist Children's Hospital in San Antonio, Texas. He is also a principal investigator of the ExCell study currently evaluating StemEx. Dr. Petropoulos is a pediatric hematologist-oncologist at the Children's Cancer Hospital at The University of Texas M. D. Anderson Cancer Center in Houston, Texas, where the Phase I study of StemEx was conducted.

In the article Dr. Chan and Dr. Petropoulos note, "Early results suggested that carlecortemcel-l infusion ... may be associated with favorable non-relapse mortality rates ... ex vivo expansion of umbilical cord blood (UCB) cells appears to be a logical approach to increase the availability of this source for hematopoietic stem cell (HSC) transplantation. Laboratory research showed that the critical element of success is to improve HSC proliferation without promoting differentiation. The manufacturing of carlecortemcel-l represents a novel methodology that fulfills this criterion. It is the only product that has reached the confirmatory stage of clinical development. A single institution study (Phase I study at M. D. Anderson Cancer Cen
'/>"/>

SOURCE Gamida Cell LTD
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Newly Published Article Details How PGS Techniques Directly Effect Successful Pregnancy Outcomes
2. Journal of American College of Cardiology Article Reports Fewer Repeat Procedures With Boston Scientifics TAXUS(R) Liberte(R) Stent
3. ACRO Comments on NEJM Article on Globalization of Clinical Research
4. Novavax Reports Positive Preclinical Results for a Novel, Broadly Cross-Protective H5N1 Pandemic Influenza Virus-like Particle (VLP) Vaccine Candidate
5. InVitrias Cellastim Showcased in Nature Article
6. Particle Sciences Expands Its Combination Product Capabilities
7. Journal of Clinical Oncology Article Highlights CellSearch(TM) Circulating Tumor Cell Test in Treatment of Metastatic Colorectal Cancer
8. Ion Mobility Diagnostic Test from Quest Diagnostics is First to Provide Direct Physical Measurement of Lipoprotein Particles, Cardiovascular Disease Indicators, Study Finds
9. Celator(R) Pharmaceuticals Successfully Uses Nanoparticles to Administer Hydrophobic Drug Combinations
10. Clinical Trial Participation Unaffected by Disclosure of Investigators Financial Stake, Food and Drug Law Journal Article Finds
11. Recent Findings from the Framingham Offspring Study Show Low Numbers of LDL Particles (LDL-P) by NMR are Associated With Fewer Heart Disease Related Events than Equivalently Low Levels of LDL Cholesterol (LDL-C).(1)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 23, 2015 Gem Pharmaceuticals announced today that the ... into the Company,s Phase 2 clinical trial.  This open-label ... lead compound, GPX-150 (an investigational medication), in approximately 30 ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
(Date:1/22/2015)... BOULDER, Colo. , Jan. 22, 2015  BiOptix is ... Klakamp as Vice President of Chemistry and Biochemistry. Scott ... Takeda Pharmaceuticals, AstraZeneca Pharmaceuticals, and Amgen throughout the course ... and development. "Scott is a nationally recognized ...
(Date:1/22/2015)... , Jan. 22, 2015  Amgen (NASDAQ: AMGN ) today ... 2014 financial results on Tuesday, Jan. 27, 2015, after the close ... a conference call with the investment community at 2 p.m. PT. ... Bradway , chairman and chief executive officer, and other members of ...
Breaking Medicine Technology:Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2Amgen Announces Webcast of 2014 Fourth Quarter and Full Year Financial Results 2
... In Follow-up Period -, EXTON, Pa., Jan. ... injections have been completed in the pivotal,Phase III ... Therapy(TM) for the treatment of,nasolabial folds, or wrinkles ... follow-up period of the study., Isolagen also ...
... CLINICAL TRIAL RESULTS PUBLISHED IN THE JOURNAL OF ... 14 BioForm Medical,Inc. (Nasdaq: BFRM ) ... randomized, blinded comparative study of nasolabial fold,treatments reporting ... more effective than Restylane(R), the leading dermal filler,on ...
Cached Medicine Technology:Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase III Wrinkle and Phase II Full Face Studies 2RADIESSE More Effective Than Restylane As Reported In a 60-Patient Clinical Trial 2RADIESSE More Effective Than Restylane As Reported In a 60-Patient Clinical Trial 3RADIESSE More Effective Than Restylane As Reported In a 60-Patient Clinical Trial 4
(Date:1/22/2015)... York, New York (PRWEB) January 22, 2015 ... http://www.vaginalmeshlawsuit2015.com/ ) in the U.S. District Court, Southern District of ... C.R. Bard, Inc. in that proceeding’s first bellwether trial. In ... request for a new trial after finding that C.R. Bard ...
(Date:1/22/2015)... 20 years, Dr. David Cruz of Cruz Chiropractic Care ... about every type of injury that can result from car accidents ... years, the team at Doctors on Liens has been ... With the combined breadth of experience between the two, ...
(Date:1/22/2015)... Recently, Weddingshe.com has added many trendy Champagne wedding ... revenues in the past three years. Today, the business announces ... According to the sales manager of the company, this is ... 2015. This point can be reflected on the discounted wedding ...
(Date:1/22/2015)... January 22, 2015 As interest in the ... care gains momentum worldwide, Rev. Eric J. Hall , ... Network (HCCN), will be the keynote speaker on January ... Israel’s public health system. , The conference, “Hope and Resilience: ...
(Date:1/22/2015)... 2015 State Forestry Institute of Mecklenburg-Vorpommern ... with support from GEOSYSTEMS, a dedicated Hexagon Geospatial and ... leverage Hexagon Geospatial’s ERDAS APOLLO for cataloging, ... as point clouds and documents. This effort will enable ...
Breaking Medicine News(10 mins):Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 3
... Iridoids and Other ... ... (TNI) today set itself apart from the superfruits of the world yet again as modern ... plant that enhances the overall ability of the body to adapt to stress. Noni assists ...
... ... Kidney Diseases recommends capsaicin as an effective skin care regimen to help relieve itching associated ... be extremely hot. Now there,s a new skin spray made with the essence of hot ... ...
... ... be a simple matter of getting information about coverage that,s already available ... making concerted efforts to direct the uninsured to coverage, efforts by ordinary ... Charles Smith-Dewey, founder of one of the Web,s most respect health insurance ...
... ... opportunity for educational institutes to discuss their security requirements and compare their current Digital ... , ... (PRWEB) March 4, 2010 -- GlobalSign Inc ( www.globalsign.com ), one of the longest ...
... found that using high-resolution CT-scans to screen for lymphangioleiomyomatosis, or ... who come to the emergency room for the first time ... online ahead of print publication in the American Thoracic Society,s ... Pulmonary LAM is a rare but serious lung ...
... , ... help consumers keep track of their calories by scanning the barcodes on food items has gone ... ... who want to keep track of their daily nutritional intake by scanning the barcodes of items ...
Cached Medicine News:Health News:Tahitian Noni Bioactive Beverages™ Are Adaptogenic 2Health News:Hot Pepper Itch Remedy Targets Kidney Disease Patients Suffering From Chronic Pruritus 2Health News:Consumer Health Insurance Site Founder: Health Reform or No Health Reform, Americans Can Help Reduce Rolls of the Uninsured 2Health News:Consumer Health Insurance Site Founder: Health Reform or No Health Reform, Americans Can Help Reduce Rolls of the Uninsured 3Health News:Consumer Health Insurance Site Founder: Health Reform or No Health Reform, Americans Can Help Reduce Rolls of the Uninsured 4Health News:Consumer Health Insurance Site Founder: Health Reform or No Health Reform, Americans Can Help Reduce Rolls of the Uninsured 5Health News:GlobalSign to Demonstrate Online Security Solutions to Educational Institutes at NERCOMP Conference 2Health News:GlobalSign to Demonstrate Online Security Solutions to Educational Institutes at NERCOMP Conference 3Health News:GlobalSign to Demonstrate Online Security Solutions to Educational Institutes at NERCOMP Conference 4Health News:GlobalSign to Demonstrate Online Security Solutions to Educational Institutes at NERCOMP Conference 5Health News:CT-scan screening for LAM in women with collapsed lung is cost-effective 2Health News:CT-scan screening for LAM in women with collapsed lung is cost-effective 3Health News:Barcode Joins the Battle of the Bulge in New iPhone App 2
Intended for the quantitative determination of triglycerides in serum or plasma. Reaction: endpoint. Wavelength: 520 nm. Linearity: 1000 mg/dL (11.3 mmol/L). Single vial, dry powder reagent....
Alkaline phosphatase FS (IFCC). For determination of alkaline phosphatase (ALP) in serum or plasma. For Hitachi 717. Controls: Trulab N and Trulab P....
Intended for the quantitative determination of alkaline phosphatase activity in serum or plasma. Kinetic reaction. 405 nm wavelength. 830 U/L at 30C linearity. Single vial, dry powder reagent....
For the direct quantitative determination of low density lipoprotein cholesterol (LDL-C) in human serum or plasma. For in vitro diagnostic use only....
Medicine Products: